Clinical Trials
60 stories related to this topic, newest first.
insidermonkey.comCervoMed Raises $10.5 Million in Private Placement
CervoMed Inc. announced a private placement expected to generate $10.5 million in gross proceeds. The company said the funds will extend its cash runway into the second quarter of 2027 and support efforts to secure a partner for Phase 3 development of neflamapimod in dementia wit…
Fox NewsSmall Subgroup Analysis Finds Stronger Heart-Failure Risk Reduction With Dapagliflozin in Cardiomyopathy Variant Carriers
A Nature Medicine analysis of the DECLARE-TIMI 58 trial found dapagliflozin produced an eightfold greater reduction in heart failure hospitalization among carriers of cardiomyopathy-linked genetic variants than among non-carriers.
WiredLife Biosciences Begins Human Trial of Cellular Rejuvenation Drug for Optic Nerve Conditions
A Boston-based company has started dosing adults in the first human study of ER-100, a therapy designed to restore function in optic-nerve cells damaged by glaucoma or NAION. The trial will track safety and side effects in roughly 18 participants over the next year.
The IndependentOxford University and Moderna to begin cancer vaccine trials this summer
A vaccine developed by Oxford University and Moderna will enter clinical testing this summer in patients with Lynch syndrome. The trial will assess whether the mRNA shot can train the immune system to destroy pre-cancerous cells before tumors form.
qz.comGilead and Merck Say HIV Pill Combination Hits Primary Goal in Phase 3 Trials
The companies reported that their long-acting combination pill reached its main efficacy target in late-stage testing.
qz.comSurvodutide Achieves 13% Weight Loss and Up to 63% Liver-Fat Reduction in Phase 3 Trial, Trailing Existing GLP-1 Drugs
Patients lost 13 percent of body weight on the highest dose after 76 weeks. Liver-fat reduction exceeded placebo by a wide margin.
Zealand Pharma's Survodutide Meets Key Targets in Phase 3 Trial but Sees 19% Discontinuation Rate Due to GI Side Effects
The Danish drugmaker's stock fell sharply after late-stage data showed 19% of patients discontinued survodutide due to gastrointestinal side effects, compared with 2.9% on placebo.
foxbusiness.comZealand Pharma Shares Fall 20% After Weight-Loss Drug Trial Shows High Discontinuation Rate
The Danish company's stock dropped sharply Monday after trial participants discontinued use of its experimental weight-loss treatment at high rates.
The GuardianNew Pancreatic Cancer Drug Doubles Survival Time in Trial
A daily pill extended median survival from 6.5 to 13.5 months for patients with advanced pancreatic cancer in a 500-person study. Separate early trials showed a smart drug shrank tumors in six common cancers, and observational data linked GLP-1 weight-loss drugs to lower cancer r…
finance.yahoo.comSurvodutide Achieves 63% Liver Fat Reduction and 13% Weight Loss in Phase 3 Obesity Trial
Boehringer Ingelheim’s weekly injectable reduced liver fat more than placebo but produced 13 percent weight loss after 76 weeks, below rates for Wegovy and Zepbound.
cnbc.comExperimental Drug Added to Standard Therapy Yields 19% Functional Cure Rate for Chronic HBV in Two Trials, Only in Already-Controlled Patients
A six-month course of an experimental drug combined with existing antivirals produced functional cures in 19 percent of participants whose chronic hepatitis B infections were already well controlled.
cnbc.comRetatrutide Shows Strong Blood-Sugar and Weight-Loss Benefits in Diabetes Trial With Limited Cardiac Events
New safety figures from Eli Lilly’s TRANSCEND-T2D-1 study were released Saturday at the American Diabetes Association meeting and published in the Lancet.
thehindubusinessline.comPfizer Reports Phase 2b Results for Monthly GLP-1 Drug Berobenatide
Pfizer's experimental GLP-1 receptor agonist berobenatide showed strong blood-sugar control and weight-loss effects in a Phase 2b trial. The company said the drug was generally well tolerated and supported further testing of once-monthly dosing.
cnbc.comPfizer and Amgen Report Midstage Data on Experimental Monthly GLP-1 Drugs for Weight Loss
Pfizer and Amgen are advancing monthly GLP-1 drugs that could reduce injections from 52 to 12 per year. Early trial data show weight loss and blood-sugar control with side effects similar to weekly versions.
Cullinan Therapeutics Presents Phase 1 Data on CLN-978 at EULAR 2026 Congress
Cullinan Therapeutics reported initial clinical results from two Phase 1 trials of CLN-978, a CD19xCD3 T cell engager, in patients with systemic lupus erythematosus and rheumatoid arthritis. The data were presented June 6 at the European Alliance of Associations for Rheumatology…
prnewswire.comRivus Pharmaceuticals Presents Preclinical Non-Human Primate Data on Oral GLP-1 Candidate RV-8451 at ADA Meeting
Rivus Pharmaceuticals announced preclinical results for its oral GLP-1 receptor agonist RV-8451 at the American Diabetes Association's 86th Scientific Sessions on June 5, 2026.
StatPatient Reports Benefit from Revolution Medicines’ Daraxonrasib as Oncologists Applaud Data but Biotech Stocks Fall
Leanna Stokes, diagnosed with metastatic pancreatic cancer in 2023, discussed her experience in a Revolution Medicines clinical trial on a June 4, 2026 podcast. Oncologists gave a standing ovation to data on the company’s drug daraxonrasib presented at last week’s American Societ…
medpagetoday.comLarge NCI-Funded Phase 3 Trial Tests Probiotic CBM588 With Immunotherapy in Advanced Kidney Cancer
A multicenter study funded by the National Cancer Institute will test whether CBM588 improves outcomes when taken with immunotherapy in nearly 700 people with advanced renal cell carcinoma.
The IndependentAI Vaccine Targets Virus Families in Early Human Trial
A DNA vaccine created with machine learning produced immune responses to multiple coronaviruses in a phase I study of 49 volunteers. Researchers plan a phase II trial with more than 200 participants. The approach aims to address shared viral features rather than individual strain…
StatPancreatic Cancer Patient in Clinical Trial Plans to Seek Expanded Access to Daraxonrasib if Needed
Amy Johnston, 35, of Gilbertsville, Pa., plans to request daraxonrasib if her current trial fails. The drug nearly doubled survival time in earlier testing and is now available through an expanded access program.
thehindu.comRezolute to Present Four Studies on Hyperinsulinism at Endocrine Society Meeting
Rezolute, Inc. will deliver one oral presentation and three poster presentations at the Endocrine Society annual meeting in Chicago from June 13-16, 2026. The presentations cover clinical trial results and outcomes data related to congenital and tumor-associated hyperinsulinism.
Substrate placeholder — needs reviewSmall Phase-2 Trial Finds 85% of Bladder Cancer Patients Cancer-Free at One Year With Added Immunotherapy
A phase-two study found that adding durvalumab to chemotherapy and radiotherapy kept cancer from returning in 46 of 54 patients. The approach may allow some patients to avoid bladder removal surgery.
BenzingaGilead’s Phase 3 IDEAL Study Shows Livdelzi Superior to Placebo on ALP Normalization in Mildly Elevated PBC Patients
Gilead Sciences released Phase 3 IDEAL study data showing Livdelzi achieved statistically significant ALP normalization versus placebo after 52 weeks in patients with inadequately controlled primary biliary cholangitis.
prnewswire.comUK to Trial Enhanced Prostate Screening for Black Men Aged 45-74 With £18m Investment
The government will invest £18 million to invite black men aged 45-74 into the Transform trial. The move follows a National Screening Committee recommendation against routine PSA testing for most men.
thisisanfield.comCrinetics Pharmaceuticals to Present Six Abstracts at ENDO 2026
Crinetics Pharmaceuticals will present six abstracts at the Endocrine Society's Annual Meeting in Chicago from June 13-16, 2026. The presentations cover clinical data on PALSONIFY for acromegaly and atumelnant for congenital adrenal hyperplasia and Cushing's syndrome.
Nbc NewsPersonalized mRNA Vaccine Shows Reduced Melanoma Recurrence in Small Phase 2 Trial
A Moderna and Merck experimental vaccine cut melanoma recurrence risk by half in a five-year trial. Results were presented June 1, 2026, at the American Society of Clinical Oncology meeting.
themarketherald.com.auAbivax Reports Positive Phase 3 Results for Bowel Disease Drug but Some Patients Developed Cancer
Abivax said its experimental drug helped patients with chronic inflammatory bowel disease in a pivotal study. Some trial participants developed cancer that the company said was unrelated to treatment.
Vor Bio Awards Stock Options, RSUs to 10 New Hires as Inducements
The Compensation Committee approved equity awards covering 73,950 shares under the 2023 Inducement Plan on June 1, 2026. The grants comply with Nasdaq Listing Rule 5635(c)(4).
news24.comPROTEUS Phase 3 Trial Finds Adding Second Perioperative Hormone Therapy to Prostatectomy Reduced Recurrence Risk in High-Risk Localized
A Phase 3 study found combining two hormone therapies before and after prostate removal produced better results than one hormone therapy in high-risk, early-stage cases. The findings may establish a third treatment path alongside surgery alone or radiation with hormone therapy.
benzinga.comRevolution Medicines Reports Pancreatic Cancer Drug Data at ASCO
New results for Revolution Medicines' daraxonrasib were presented at the ASCO conference over the weekend. A pancreatic cancer expert described an emotional reaction after treating patients with the data.
livemint.comEli Lilly Tests One-Time Gene-Editing Infusion for High Cholesterol
Eli Lilly is conducting early trials of VERVE-102, a gene-editing therapy designed to lower LDL cholesterol after a single four-hour infusion. An initial study of 35 participants showed LDL reductions of up to 62 percent, with effects lasting up to 18 months in more than one-thir…
citizen.co.zaExperimental Lung Cancer Drug Cuts Death Risk by 34% in China Trial
An ivonescimab-based therapy from Akeso and Summit Therapeutics lowered death risk by 34% versus standard care in a late-stage Chinese study. Median survival reached 27.9 months compared with 23.7 months for patients on a PD-1 drug plus chemotherapy.
singularityhub.comCancer Shot Eliminated Tumors in 15 of 102 Trial Participants
A clinical trial of an experimental cancer injection showed tumor shrinkage in 43 patients and complete tumor elimination in 15 others. The results come from a study involving 102 participants.
fortune.comDrug Doubles Survival in Metastatic Pancreatic Cancer Trial
An international trial presented Sunday showed daraxonrasib doubled median survival for patients with metastatic pancreatic cancer compared with standard chemotherapy. France has expanded a personalized screening program to eight additional centers.
The TimesResearchers Report Daily Pill Shows Promise in Cancer Treatment Studies
A research team announced results from trials of an oral medication designed to target cancer cells. The findings were presented as a potential advance for patients undergoing treatment.
Science NewsDaraxonrasib Extends Median Survival by Six Months vs Chemotherapy in Previously Treated Advanced Pancreatic Cancer
A Phase III trial of 500 patients found the oral drug daraxonrasib extended median survival to 13 months versus less than seven months with chemotherapy. Results were presented May 31, 2026 at ASCO and published the same day in the New England Journal of Medicine.
Science NewsPill Nearly Doubles Survival Time in Pancreatic Cancer Trial
A once-daily pill nearly doubled average survival for patients with advanced pancreatic cancer in a 500-patient randomized study. Patients on the drug lived 13.2 months on average versus 6.6 months on chemotherapy.
benzinga.comIvonescimab Shows 34% Reduction in Death Risk vs. Standard Therapy in China-Only Squamous NSCLC Trial
Data from a China-only trial of ivonescimab were presented May 31, 2026, at the American Society of Clinical Oncology meeting in Chicago and published simultaneously in The Lancet.
Ivonescimab Plus Chemotherapy Extends Median Survival by Four Months vs Tislelizumab in Chinese Lung Cancer Trial
Data released Sunday showed ivonescimab reduced death risk by 34 percent versus a PD-1 drug plus chemotherapy. The results are being presented at the ASCO meeting.
Amivantamab Shows Tumor Response in 43 of 102 Patients With Advanced Head and Neck Cancer
An 11-nation trial of the Johnson & Johnson drug showed tumor shrinkage in more than a third of patients whose disease had returned or spread. Median survival reached 12.5 months after treatment began.
StatBioNTech and Pfizer Present Bispecific Antibody Data at Oncology Meeting
BioNTech and Pfizer presented data on bispecific antibodies at the American Society of Clinical Oncology annual meeting. The companies highlighted results from studies involving new immunotherapies. Coverage also noted comments from an FDA official on agency operations.
The GuardianAmivantamab Shows Tumor Responses in 43 of 102 Patients with Advanced Head and Neck Cancer
An international trial found the Johnson & Johnson drug shrank or eliminated tumors in 43 of 102 patients whose disease had resisted prior chemotherapy and immunotherapy. Results will be presented Sunday at the American Society of Clinical Oncology meeting in Chicago.
prnewswire.comGalleri Blood Test Shows No Significant Reduction in Advanced Cancers but Cuts Stage 4 Diagnoses by 14% in Large NHS Trial
A multi-cancer early detection blood test did not reduce late-stage diagnoses when added to standard screening. Data were presented at the American Society of Clinical Oncology meeting in Chicago.
/cdn.vox-cdn.com/uploads/chorus_asset/file/24856972/236744_Withings_Body_Smart_VSong_0003.jpg)
theverge.comRetatrutide Shows 28 Percent Body Weight Reduction in Trials
Retatrutide, a triple-receptor drug targeting GLP-1, GIP, and glucagon, produced the largest average weight loss reported so far. The medication also carries additional safety considerations.
foxbusiness.comFDA Rejects Experimental Melanoma Drug Twice Over Study Design
The Food and Drug Administration turned down an experimental melanoma treatment on two separate occasions after raising questions about how the supporting clinical study was structured. The agency cited concerns with the trial's design as the basis for both rejections.
koreaherald.comAptose Biosciences Delays Closing of Hanmi Acquisition to June
Aptose Biosciences said regulatory approvals in South Korea are still pending for its planned acquisition by Hanmi Pharmaceutical. The companies now target closing in June and have received an additional loan advance to continue operations.
foxnews.comGene Therapies Advance to Human Trials for Heart Regeneration
Researchers have begun the first clinical trial of a gene therapy designed to grow new heart-muscle cells. At least four additional regenerative gene therapies for heart conditions are in development by companies.
financialpost.comXPRIZE Healthspan Competition Selects 10 Teams for Aging Research Trials
The $101 million XPRIZE Healthspan program will require selected teams to conduct yearlong randomized controlled trials testing therapies aimed at restoring muscle, cognition, and immune function in older adults. The winner is scheduled to be announced in 2030.
New York PostNew drug achieves functional cure in 20 percent of chronic hepatitis B patients
A clinical trial found that bepirovirsen rendered the hepatitis B virus undetectable in 20 percent of treated patients after 48 weeks. The study enrolled more than 1,838 participants across 29 countries. No patients receiving placebo achieved the same outcome.
The IndependentGSK Hepatitis B Drug Shows Functional Cure in 20 Percent of Trial Patients
Two international studies found that bepirovirsen produced sustained viral suppression in roughly one-fifth of participants after treatment ended. The drug is under FDA fast-track review with a decision expected in October.
StatGSK Drug Achieves Functional Cure in 19-20% of Hepatitis B Patients
Two Phase 3 trials showed GSK's bepirovirsen produced functional cures in nearly one-fifth of chronic hepatitis B patients. Current nucleoside analogue treatments reach functional cures in only 1-3% of cases. The company has submitted the drug for regulatory approval.
prnewswire.comResearchers Report Kilogram-Scale Synthesis of Cholesterol Drug Enlicitide
A Science study describes a new production method for enlicitide, a peptide in Phase 3 trials for lowering LDL cholesterol. The route uses engineered enzymes and crystallization steps to reduce reaction count and raise yield.
foxnews.comCancer Immunotherapy Pipeline Expands With Multiple New Drug Classes
More than 2,500 cancer immunotherapy programs are now active. Fifteen years after the first checkpoint inhibitor approval, several additional drug types have reached FDA approval or late-stage testing.
thehindu.comMerck drug combination reduces lung cancer progression risk in trial
A Merck antibody-drug conjugate combined with Keytruda lowered the risk of tumor progression by 65 percent in a Phase 3 lung cancer study. The results come from an abstract released ahead of the American Society of Clinical Oncology meeting.
bbc.co.ukEnhanced Games Releases Substance Use Data Ahead of Las Vegas Event
Enhanced Games reported substance usage rates from its IRB-approved clinical trial before the first competition scheduled for May 24 at Resorts World Las Vegas. The data showed high percentages of athletes using performance-related substances.
finance.yahoo.comEli Lilly Reports Retatrutide Helped Patients Lose 70 Pounds in Trial
Eli Lilly announced clinical trial results showing its experimental obesity drug retatrutide produced greater weight loss than its existing treatments Zepbound and Wegovy. The company said participants lost an average of 70 pounds over 80 weeks.
manilatimes.netPerspective Therapeutics to Present Clinical Updates at 2026 ASCO Meeting
Perspective Therapeutics announced it will present data from three ongoing cancer treatment studies at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.
StatMerck-Kelun Drug Reduced Lung Cancer Progression Risk by 65 Percent in Trial
Phase 3 study results showed that a targeted chemotherapy developed by Kelun-Biotech and licensed to Merck reduced tumor progression risk by 65 percent in patients with advanced non-small cell lung cancer. A preliminary survival benefit was observed but requires longer follow-up…
Nbc NewsEli Lilly Weight Loss Drug Retatrutide Shows Up to 30 Percent Body Weight Loss in Trial
Eli Lilly reported that its experimental drug retatrutide produced average weight loss of 28 percent after 80 weeks and up to 85 pounds in some patients. The results come from a phase 3 trial of roughly 2,300 people and remain comparable to outcomes from bariatric surgery.
benzinga.comEli Lilly Reports Retatrutide Weight Loss Results in Phase 3 Trial
Eli Lilly reported results from a late-stage trial of its obesity drug retatrutide. Patients who stayed on the highest dose lost an average of 28.3 percent of their body weight after 80 weeks.